View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Oct. 31, 2019	Dec. 16, 2019	Apr. 30, 2019
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-K
Document Period End Date	Oct. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 28,098,000
Entity Common Stock, Shares Outstanding		50,211,424
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Balance Sheets - USD ($) $ in Thousands	Oct. 31, 2019	Oct. 31, 2018
Current assets:
Cash and cash equivalents	$ 32,363	$ 44,141
Restricted cash		977
Accounts receivable		1,664
Deferred expenses	2,353	2,072
Prepaid expenses and other current assets	1,433	1,611
Total current assets	36,149	50,465
Property and equipment (net of accumulated depreciation)	4,350	6,684
Intangible assets (net of accumulated amortization)	4,575	4,838
Other assets	183	280
Total assets	45,257	62,267
Current liabilities:
Accounts payable	976	5,646
Accrued expenses	3,478	6,185
Deferred revenue		4,476
Common stock warrant liability	19	6,517
Other current liabilities	48	48
Total current liabilities	4,521	22,872
Deferred revenue - net of current portion		14,189
Other liabilities	1,205	1,155
Total liabilities	5,726	38,216
Commitments and contingencies - Note 9
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2019 and 2018. Liquidation preference of $0 at October 31, 2019 and 2018.
Common stock - $0.001 par value; 170,000,000 shares authorized, 50,201,671 and 4,634,189 shares issued and outstanding at October 31, 2019 and 2018.	50	5
Additional paid-in capital	423,750	391,703
Accumulated deficit	(384,269)	(367,657)
Total stockholders' equity	39,531	24,051
Total liabilities and stockholders' equity	$ 45,257	$ 62,267

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Oct. 31, 2019	Oct. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Series B Preferred stock, shares issued	0	0
Series B Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	50,201,671	4,634,189
Common stock, shares outstanding	50,201,671	4,634,189

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Oct. 31, 2019	Oct. 31, 2018
Income Statement [Abstract]
Revenue	$ 20,884	$ 6,063
Operating expenses:
Research and development expenses	26,677	56,970
General and administrative expenses	12,179	19,472
Total operating expenses	38,856	76,442
Loss from operations	(17,972)	(70,379)
Other income (expense):
Interest income	435	577
Net changes in fair value of derivative liabilities	2,589	3,400
Loss on shares issued in settlement of warrants	(1,607)
Other expense	(7)	(63)
Net loss before income tax benefit	(16,562)	(66,465)
Income tax expense	50	50
Net loss	$ (16,612)	$ (66,515)
Net loss per common share, basic and diluted	$ (1.09)	$ (19.36)
Weighted average number of common shares outstanding, basic and diluted	15,207,637	3,434,824

Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Oct. 31, 2017	$ 3	$ 355,399	$ (301,142)	$ 54,260
Balance, shares at Oct. 31, 2017	2,744,196
Stock-based compensation		7,028		7,028
Stock-based compensation, shares	50,828
Tax withholdings paid related to net share settlement of equity awards		(87)		(87)
Tax withholdings paid on equity awards		(474)		(474)
Tax shares sold to pay for tax withholdings on equity awards		460		460
Issuance of shares to employees under ESPP Plan		43		43
Issuance of shares to employees under ESPP Plan, shares	2,611
ESPP Expense		7		7
Advaxis at-the-market sales		2,659		2,659
Advaxis at-the-market sales, shares	58,776
Advaxis public offerings	$ 2	26,668		26,670
Advaxis public offerings, shares	1,777,778
Net Loss			(66,515)	(66,515)
Balance at Oct. 31, 2018	$ 5	391,703	(367,657)	24,051
Balance, shares at Oct. 31, 2018	4,634,189
Stock-based compensation		2,002		2,002
Stock-based compensation, shares	12,220
Tax withholdings paid on equity awards		(15)		(15)
Tax shares sold to pay for tax withholdings on equity awards		14		14
Issuance of shares to employees under ESPP Plan		20		20
Issuance of shares to employees under ESPP Plan, shares	7,435
ESPP Expense		2		2
Advaxis public offerings	$ 13	24,458		$ 24,471
Advaxis public offerings, shares	13,150,000			17,869,662
Pre-funded warrant exercises	$ 13			$ 13
Pre-funded warrant exercises, shares	13,656,000
Warrant exercises	$ 18	104		122
Warrant exercises, shares	17,884,962
Warrant exchange	$ 1	5,462		5,463
Warrant exchange, shares	856,865
Net Loss			(16,612)	(16,612)
Balance at Oct. 31, 2019	$ 50	$ 423,750	$ (384,269)	$ 39,531
Balance, shares at Oct. 31, 2019	50,201,671

Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statement of Cash Flows - USD ($) $ in Thousands	Oct. 31, 2019	Oct. 31, 2018
OPERATING ACTIVITIES
Net loss	$ (16,612)	$ (66,515)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	2,002	6,983
Employee stock purchase plan expense	3	7
Gain on change in value of warrants	(2,589)	(3,400)
Loss on shares issued in settlement of warrants	1,607
Loss on disposal of property and equipment	344	614
Loss on write-down of property and equipment	943
Abandonment of intangible assets	1,104	1,047
Depreciation expense	1,097	1,113
Amortization expense of intangible assets	386	388
Net accretion of premiums		(6)
Change in operating assets and liabilities:
Accounts Receivable	1,664	(153)
Prepaid expenses and other current assets	(103)	836
Income taxes receivable		4,453
Other assets	18	151
Accounts payable and accrued expenses	(7,377)	(1,954)
Deferred revenue	(18,665)	(5,809)
Other liabilities	50	116
Net cash used in operating activities	(36,128)	(62,129)
INVESTING ACTIVITIES
Purchases of short-term investment securities		(12,487)
Proceeds from maturities of short-term investment securities		58,891
Purchase of property and equipment	(54)	(1,425)
Proceeds from disposal of property and equipment	83
Cost of intangible assets	(1,227)	(1,416)
Net cash (used in) provided by investing activities	(1,198)	43,563
FINANCING ACTIVITIES
Net proceeds of issuance of common stock and pre-funded warrants	24,471	39,246
Warrant exercises	68
Pre-funded warrant exercises	13
Proceeds from employee stock purchase plan	20	52
Tax withholdings paid related to net share settlement of equity awards		(87)
Employee tax withholdings paid on equity awards	(15)	(474)
Tax shares sold to pay for employee tax withholdings on equity awards	14	460
Net cash provided by financing activities	24,571	39,197
Net (decrease) increase in cash, cash equivalents and restricted cash	(12,755)	20,631
Cash, cash equivalents and restricted cash at beginning of year	45,118	24,487
Cash, cash equivalents and restricted cash at end of year	32,363	45,118
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows:
Cash and cash equivalents	32,363	44,141
Restricted cash		977
Total cash, cash equivalents and restricted cash shown in statements of cash flows	32,363	45,118
Supplemental Disclosures of Cash Flow Information
Cash paid for taxes	50	50
Supplemental Schedule of Noncash Investing and Financing Activities
Shares issued in settlement of warrants	5,463
Warrant liability reclassified into equity	54
Reclass of security deposit to property and equipment for delivered equipment	$ 79

Nature of Operations and Basis of Presentation

12 Months Ended

Oct. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations and Basis of Presentation

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”) based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm Technology^TM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;

	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and

	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

In June 2019, Advaxis announced that it is closing the AIM2CERV Phase 3 clinical trial with axalimogene filolisbac (AXAL) in high-risk locally advanced cervical cancer and in October 2019, Advaxis announced that it has enrolled its last patient in its ADXS-NEO program in monotherapy and will not continue into Part B of this study.

Going Concern and Managements Plans

The Company has not yet commercialized any human products and the products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for an extended period of time. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern within one year after the date the financial statements are issued.

Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its common stock, clinical collaborations, option and warrant exercises, and interest income. From October 2013 through October 2019, the Company raised approximately $292.2 million in gross proceeds ($27.0 million in fiscal year 2019) from various public and private offerings of its common stock.

As of October 31, 2019, the Company had approximately $32.4 million in cash and cash equivalents. Although the Company believes that it expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least January 2021, the actual amount of cash that it will need to operate is subject to many factors. Management’s plans to mitigate an expected shortfall of capital and to support future operations include obtaining additional funds through partnerships or strategic or financing investors. The Company has reduced its operating expenses to $38.9 million for the year ended October 31, 2019 as compared to $76.4 million during the comparable prior period. Furthermore, the Company expects operating expenses to be approximately $29 million for fiscal year 2020, which includes approximately $6 million in non-recurring costs related to programs that are winding down.

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.

Summary of Significant Accounting Policies

12 Months Ended

Oct. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used when accounting for such items as the fair value and recoverability of the carrying value of property and equipment and intangible assets (patents and licenses), deferred expenses and deferred revenue, the fair value of options, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may or may not differ from estimates.

Reclassification

Certain amounts in the prior period financial statements have been reclassified to confirm to the presentation of the current period financial statements. The reclassifications had no effect on the previously reported net loss.

Revenue Recognition

Effective November 1, 2018, the Company adopted ASC Topic 606, Revenue form Contracts with Customers (ASC 606), using the modified retrospective transition method. Under this method, results for reporting periods beginning on November 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605, Revenue Recognition (ASC 605). The Company only applied the modified retrospective transition method to contracts that were not completed as of November 1, 2018, the effective date of adoption for ASC 606. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.

Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

Exclusive Licenses. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a performance obligation is distinct from the other performance obligations, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a performance obligation for its intended purpose without the receipt of the remaining performance obligation, whether the value of the performance obligation is dependent on the unsatisfied performance obligation, whether there are other vendors that could provide the remaining performance obligation, and whether it is separately identifiable from the remaining performance obligation. For licenses that are combined with other performance obligation, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods.

Research and Development Services. The performance obligations under the Company’s collaboration agreements may include research and development services to be performed by the Company on behalf of the partner. Payments or reimbursements resulting from the Company’s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts.

Milestone Payments. At the inception of each arrangement that includes research or development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. An output method is generally used to measure progress toward complete satisfaction of a milestone. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Royalties. For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.

Collaborative Arrangements

The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. Amounts that are owed to collaboration partners are recognized as an offset to collaboration revenue as such amounts are incurred by the collaboration partner. For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above under ASC 606.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $30.9 million is subject to credit risk at October 31, 2019. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Restricted Cash and Letter of Credit

During July 2017 and January 2018, the Company established two letters of credit with a financial institution as security for the purchase of custom equipment and as security for application fees associated with the Company’s Marketing Authorization Application (“MAA”) in Europe. The letters of credit were collateralized by cash which was unavailable for withdrawal or for usage for general obligations. During the year ended October 31, 2019, the two letters of credit were terminated and as of October 31, 2019 the Company has no restricted cash balance.

Deferred Expenses

Deferred expenses consist of advanced payments made on research and development projects. Expense is recognized in the Statement of Operations as the research and development activity is performed.

Property and Equipment

Property and equipment is stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from three to ten years.

When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

Intangible assets are recorded at cost and include patents and patent application costs, licenses and software. Intangible assets are amortized on a straight-line basis over their estimated useful lives ranging from 3 to 20 years. Patent application costs are written-off if the application is rejected, withdrawn or abandoned.

Impairment of Long-Lived Assets

The Company reviews its long-lived assets, including property and equipment and intangible assets, for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, an impairment loss is recognized in the Statement of Operations based on the excess of the carrying amount over the fair value of the asset.

Net Income (Loss) per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. In the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.

	As of October 31,
	2019		2018
Warrants		432,142		944,635
Stock options		560,490		330,071
Restricted stock units		14,706		32,614
Total		1,007,338		1,307,320

Research and Development Expenses

Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, and related overhead costs.

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations, depending on the nature of the services provided by the employees or consultants.

The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its common stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.

The Company accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants.

Fair Value of Financial Instruments

The carrying value of financial instruments, including cash and cash equivalents, restricted cash and accounts payable approximated fair value as of the balance sheet date presented, due to their short maturities.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Monte Carlo simulation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

Recent Accounting Standards

In February 2016, the Financial Accounting Standards Board, (“FASB”), issued Accounting Standards Update, (“ASU”), No. 2016-02, Leases (Topic 842), which establishes a comprehensive new lease accounting model. The new standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than 12 months. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018, with early adoption permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, including a number of optional practical expedients that entities may elect to apply. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, an update which provides another transition method, in addition to the existing modified retrospective transition method, by allowing entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted Topic 842 effective November 1, 2019 using a modified retrospective method and will not restate comparative periods. Upon adoption, the Company recorded a right-to-use asset of approximately $5.3 million and a corresponding lease liability of approximately $6.6 million on the Company’s balance sheet with the difference relating to reclassifications of the deferred rent liability and lease incentive obligation as reductions to the right-of-use asset for its operating lease. Adoption of the new lease standard will not have a significant impact on the Company’s statement of operations.

Recently Adopted Accounting Standards

In May 2014, FASB issued ASU No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. ASU No. 2014-09 superseded the revenue recognition requirements in ASC 605 and created ASC 606 described above. In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. Effective November 1, 2018, the Company adopted ASC 606 using the modified retrospective transition method.

As a result of adopting ASC 606, the Company made reclassifications to the balance sheet and income statement. Net income (loss) was not impacted by the adoption of ASC 606. A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below (in thousands):

	Impact of ASC 606 Adoption on Balance Sheet as of November 1, 2018
(in thousands)	As reported under ASC 606		Adjustments			Balances without adoption of ASC 606
Accounts receivable	$	1,664	$	1,664		$	-
Prepaid expenses and other current assets	$	1,611	$	(1,664	)	$	3,275

A summary of the amount by which each financial statement line item was affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to the adoption of ASC 606 is set forth in the tables below.

	Impact of ASC 606 Adoption on Balance Sheet as of October 31, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,433	$	-	$	1,433

	Impact of ASC 606 Adoption on Statement of Operations for the Year Ended October 31, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Revenue	$	20,884	$	1,960	$	18,924
Research and Development Expenses	$	30,320	$	1,960	$	28,360

	Impact of ASC 606 Adoption on Statement of Cash Flows for the Year Ended October 31, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,433		-		1,433

The most significant change to the Company’s accounting for revenue as a result of the adoption of ASC 606 relates to its treatment of clinical development payments it receives in its collaboration and licensing agreement with Amgen, Inc. (“Amgen”). Under ASC 605, the Company accounted for the clinical development payments as a reduction of research and development expenses in the statement of operations. Under ASC 606, the Company accounted for the reimbursements for research and development costs as revenue. For further discussion of the adoption of this standard, see Note 8.

In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606” (“ASU 2018-18”). The amendments in ASU 2018-18 make targeted improvements to generally accepted accounting principles (GAAP) for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in Topic 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments should be applied retrospectively to the date of initial application of Topic 606. The Company adopted this guidance effective November 1, 2018 using the modified retrospective approach. There was no impact on the Company’s financial statements.

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718) —Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). The amendments in ASU 2018-07 expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. ASU 2018-07 is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company adopted this guidance effective as of February 1, 2019. There was no impact on the Company’s financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash (ASU No. 2016-18). The amendments in ASU No. 2016-18 require an entity to reconcile and explain the period-over-period change in total cash, cash equivalents and restricted cash within its statements of cash flows. ASU No. 2016-18 was effective for the Company on November 1, 2018. The Company adopted ASU No. 2016-18 effective November 1, 2018 using a full retrospective approach and it did not have a significant impact on its financial statements and related disclosures.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Property and Equipment

12 Months Ended

Oct. 31, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment

3. PROPERTY AND EQUIPMENT

Property and equipment consists of the following (in thousands):

	October 31,
	2019			2018
Leasehold improvements	$	2,335		$	2,321
Laboratory equipment		3,405			5,510
Furniture and fixtures		744			746
Computer equipment		409			409
Construction in progress		83			17
Total property and equipment		6,976			9,003
Accumulated depreciation and amortization		(2,626	)		(2,319	)
Net property and equipment	$	4,350		$	6,684

Depreciation expense for each of the years ended October 31, 2019 and 2018 was approximately $1.1 million. Disposals of laboratory equipment resulted in losses of approximately $0.3 million and $0.6 million for the years ended October 31, 2019 and 2018, respectively, that was charged to research and development expenses in the statement of operations

Management has reviewed its property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. During the years ended October 31, 2019 and 2018, the Company recorded impairment losses on idle laboratory equipment of $0.9 million and $0, respectively, that was charged to research and development expenses in the statement of operations. Fair value for the idle assets was determined by a quoted purchase price for the assets.

Intangible Assets

12 Months Ended

Oct. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. INTANGIBLE ASSETS

Intangible assets consist of the following (in thousands):

	October 31,
	2019			2018
Patents	$	5,833		$	5,970
License		777			777
Software		117			117
Total intangibles		6,727			6,864
Accumulated amortization		(2,152	)		(2,026	)
Net intangible assets	$	4,575		$	4,838

The expirations of the existing patents range from 2019 to 2039 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of approximately $1.1 million and $1.0 million were abandoned and were charged to general and administrative expenses in the statement of operations for the years ended October 31, 2019 and 2018, respectively. Intangible asset amortization expense that was charged to general and administrative expense in the statement of operations was approximately $0.4 million for each of the years ended October 31, 2019 and 2018, respectively.

Management has reviewed its intangible assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA ADXS-HER2 and other products that are in development or out-licensed. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding our studies and developing its intellectual property, the Company would likely record an impairment to certain of these assets.

At October 31, 2019, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

2020	$	366
2021		346
2022		346
2023		346
2024		346
Thereafter		3,171
Total	$	4,575

Accrued Expenses

12 Months Ended

Oct. 31, 2019

Payables and Accruals [Abstract]

Accrued Expenses

5. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses (in thousands):

	October 31,
	2019		2018
Salaries and other compensation	$	158	$	2,035
Vendors		3,194		3,660
Professional fees		126		490
Total accrued expenses	$	3,478	$	6,185

Common Stock Purchase Warrants and Warrant Liability

12 Months Ended

Oct. 31, 2019

Common Stock Purchase Warrants And Warrant Liability

Common Stock Purchase Warrants and Warrant Liability

6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

As of October 31, 2019, there were outstanding warrants to purchase 432,142 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	-		359,838	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		72,279	September 2024	September 2018 Public Offering
	Grand Total		432,142

As of October 31, 2018, there were outstanding warrants to purchase 944,635 shares of our common stock with exercise prices ranging from $22.50 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	281.25		25	N/A	Other Warrants
$	56.25		166	March 2019	March 2014 Public Offering- Placement Agent
$	22.50		944,444	September 2024	September 2018 Public Offering
	Grand Total		944,635

A summary of warrant activity was as follows (In thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2017		206,160		$	75.00		.92	$	-
Issued		944,444			22.50
Expired		(205,969	)		75.00
Outstanding and exercisable warrants at October 31, 2018		944,635		$	22.50		5.87	$	-
Issued		31,885,500
Exercised *		(31,540,962	)
Exchanged		(856,865	)
Expired		(166	)
Outstanding and exercisable warrants at October 31, 2019		432,142		$	0.08		4.76	$	114,069

* Includes the cashless exercise of 17,869,662 warrants that resulted in the issuance of 17,869,662 shares of common stock.

At October 31, 2019, the Company had 359,863 of its total 432,142 outstanding warrants classified as equity (equity warrants). At October 31, 2018, the Company had 191 of its total 944,635 outstanding warrants classified as equity warrants. At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders equity section of the balance sheet.

Shares Issued in Settlement of Liability Warrants

On March 14, 2019, the Company entered into private exchange agreements with certain holders of warrants issued in connection with the Company’s September 2018 public offering of common stock and warrants. The warrants being exchanged provided for the purchase of up to an aggregate of 856,865 shares of the Company’s common stock at an exercise price of $22.50, with an expiration date of September 11, 2024. Pursuant to such exchange agreements, the Company issued 856,865 shares of common stock to the investors in exchange for such warrants on a 1:1 basis. The exchange of warrants for common stock caused the down round provision to be triggered for the first time and the exercise price of the warrants that were not exchanged were reduced from $22.50 to $4.50. The warrants were valued at approximately $3.9 million on the March 14, 2019 using the Monte Carlo simulation model. In determining the fair warrant of the warrants issued on March 14, 2019, the Company used the following inputs in its Monte Carlo simulation model: exercise price $22.50, stock price $6.45, expected term 5.50 years, volatility 96.37% and risk free interest rate 2.44%. In connection with the exchange of warrants for common stock, the Company recorded a loss of approximately $1.6 million as the fair value of the shares issued exceeded the fair value of warrants exchanged.

Warrant Liability

At October 31, 2019, the Company had 72,279 of its total 432,142 outstanding warrants classified as liabilities (liability warrants). As of October 31, 2018, the Company had 944,444 of its total 944,635 outstanding warrants classified as liabilities (liability warrants). These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of October 31, 2018, the down round feature was not triggered. In April 2019, the down round feature was triggered a second time due to the sale of 2,500,000 common shares (see Note 11) and the exercise price of the warrants were reduced from $4.50 to $3.72. In July 2019, the down round feature was triggered a third time due to the sale of 10,650,000 common shares and 13,656,000 pre-funded warrants (see Note 11) and the exercise price of the warrants were reduced from $3.72 to $0.372. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which net cash settlement would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. During the year ended October 31, 2018, 944,444 warrants were issued at an exercise price of $22.50 with a term of six years. The warrants were valued at approximately $9.9 million on the September 11, 2018 issuance using the Monte Carlo simulation model. In determining the fair warrant of the warrants issued on September 11, 2018, the Company used the following inputs in its Monte Carlo simulation model: exercise price $12.75, stock price $22.50, expected term 6 years, volatility 99.21% and risk free interest rate 2.91%.

At October 31, 2019 and October 31, 2018, the fair value of the warrant liability was approximately $19,000 and $6.5 million, respectively. For the years ended October 31, 2019 and 2018, the Company reported income of approximately $2.6 million and $3.4 million, respectively, due to changes in the fair value of the warrant liability.

In measuring the warrant liability, the Company used the following inputs in its Monte Carlo simulation model:

	October 31, 2019			October 31, 2018
Exercise Price	$	0.37		$	22.50
Stock Price	$	0.32		$	8.40
Expected Term		4.87 years			5.87 years
Volatility %		100.99	%		97.47	%
Risk Free Rate		1.51	%		3.03	%

Share Based Compensation

12 Months Ended

Oct. 31, 2019

Share-based Payment Arrangement [Abstract]

Share Based Compensation

7. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the statement of operations by expense category for the years ended October 31, 2019 and 2018 (in thousands):

	Year Ended October 31,
	2019		2018
Research and development	$	1,036	$	2,836
General and administrative		966		4,147
Total	$	2,002	$	6,983

Amendments

The Advaxis, Inc. 2015 Incentive Plan (the “2015 Plan”) was originally ratified and approved by the Company’s stockholders on May 27, 2015. Subject to proportionate adjustment in the event of stock splits and similar events, the aggregate number of shares of common stock that may be issued under the 2015 Plan is 240,000 shares, plus a number of additional shares (not to exceed 43,333) underlying awards outstanding as of the effective date of the 2015 Plan under the prior plan that thereafter terminate or expire unexercised, or are cancelled, forfeited or lapse for any reason.

At the Annual Meeting of Stockholders of the Company held on March 10, 2016, the stockholders ratified and approved an amendment to the 2015 Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan from 240,000 shares to 306,667 shares. Furthermore, the stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 45,000,000 shares of common stock to 65,000,000 shares of common stock.

At the Annual Meeting of Stockholders of the Company held on April 5, 2017, the stockholders ratified and approved an amendment to the 2015 Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan from 306,667 shares to 406,667 shares. The amendment also included a provision that provides for pre-defined annual increases in the number of shares available for issuance under the Plan equal to the lesser of: (i) 5% of the total number of shares of common stock outstanding, (ii) 166,667, or (iii) a lesser number determined by the Board of Directors. On January 1, 2018, 137,743 shares, or 5% of the total number of shares of common stock outstanding, were added to the 2015 Plan.

At the Annual Meeting of Stockholders of the Company held on March 21, 2018, the stockholders ratified and approved an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 65,000,000 shares of common stock to 95,000,000 shares of common stock. On January 1, 2019, 166,667 shares were added to the 2015 Plan.

At the Annual Meeting of Stockholders of the Company held on February 21, 2019, the Company’s stockholders voted to approve an amendment to increase the number of authorized shares of common stock from 95,000,000 to 170,000,000 and also voted to approve an amendment to allow the Company to execute a reverse stock split of common stock at the discretion of the Board of Directors. The amendment to increase the number of authorized shares of common stock became effective upon filing of the amendment with the Secretary of State of the State of Delaware on February 28, 2019. Additionally, on March 29, 2019, the Company executed a 1 for 15 reverse stock split. As of October 31, 2019, there were 26,161 shares available for issuance under the 2015 Plan.

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the year ended October 31, 2019 and 2018 is as follows:

	Number of RSU’s			Weighted-Average Grant Date Fair Value
Unvested as of October 31, 2017		90,870		$	128.10
Granted		27,330			29.55
Vested		(53,873	)		115.65
Cancelled		(31,713	)		123.45
Unvested as of October 31, 2018		32,614		$	70.41
Vested		(12,257	)		78.41
Cancelled		(5,651	)		112.39
Unvested as of October 31, 2019		14,706		$	47.62

The fair value of the RSUs as of the respective vesting dates was approximately $51,000 and $1.6 million for the years ended October 31, 2019 and 2018, respectively.

As of October 31, 2019, there was approximately $0.3 million of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.20 years.

As of October 31, 2019, the aggregate intrinsic value of non-vested RSUs was approximately $5,000.

Employee Stock Awards

Common stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 12,245 shares and 48,874 shares (45,830 shares on a net basis after employee taxes) during the years ended October 31, 2019 and 2018, respectively. Total stock compensation expense associated with these awards for the years ended October 31, 2019 and 2018 was approximately $0.8 million and $3.1 million, respectively.

Included in compensation expense for the year ended October 31, 2018 was approximately $0.1 million and $0.3 million, respectively, recognized as a result of the modification of certain RSU’s associated with the resignation of the Company’s Chief Financial Officer in April 2018 and Chief Operating Officer in June 2018. Pursuant to the separation agreements, the vesting was accelerated on all of the outstanding RSU’s.

Director Stock Awards

During the years ended October 31, 2019 and 2018, common stock issued to the Directors for compensation related to board and committee membership was 0 shares and 5,000 shares, respectively. During the years ended October 31, 2019 and 2018, total stock compensation expense to the Directors was $0 and $0.2 million, respectively.

Stock Options

A summary of changes in the stock option plan for the years ended October 31, 2019 and 2018 is as follows (in thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding as of October 31, 2017		259,571		$	187.65		5.72	$	-
Granted		167,871			30.90
Cancelled or expired		(97,371	)		137.10
Outstanding as of October 31, 2018		330,071		$	122.79		6.56	$	-
Granted		265,882			2.36
Cancelled or expired		(35,463	)		29.52
Outstanding as of October 31, 2019		560,490		$	71.56		7.34	$	1
Vested and exercisable at October 31, 2019		240,015		$	155.25		4.50	$	-

The following table summarizes information about the outstanding and exercisable options at October 31, 2019:

Options Outstanding										Options Exercisable
				Weighted		Weighted						Weighted		Weighted
				Average		Average						Average		Average
Exercise		Number		Remaining		Exercise		Intrinsic		Number		Remaining		Exercise		Intrinsic
Price Range		Outstanding		Contractual		Price		Value		Exercisable		Contractual		Price		Value
$	.30-$10.00		249,329		9.69	$	2.35	$	1		178		8.98	$	9.00	$	-
$	10.01-$100.00		119,753		8.53	$	29.70	$	-		52,846		8.17	$	34.15	$	-
$	100.01-$200.00		101,490		3.97	$	167.11	$	-		97,073		3.85	$	169.45	$	-
$	200.01-$318.75		89,918		3.04	$	211.39	$	-		89,918		3.04	$	211.39	$	-

The fair value of each option granted from the Company’s stock option plans during the years ended October 31, 2019 and 2018 was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s common stock price, (ii) the periods of time over which employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Company’s common stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating expected lives of the options. The Company used their own historical volatility in determining the volatility to be used. The expected term of the stock option grants was calculated using the “simplified” method in accordance with the SEC Staff Accounting Bulletin 107. The “simplified” method was used since the Company believes its historical data does not provide a reasonable basis upon which to estimate expected term and the Company does not have enough option exercise data from its grants issued to support its own estimate as a result of vesting terms and changes in the stock price. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

The following table provides the weighted average fair value of options granted to directors and employees and the related assumptions used in the Black-Scholes model:

	Year Ended
	October 31, 2019			October 31, 2018
Weighted average fair value of options granted	$	1.84		$	1.61
Expected term		5.50-6.51 years			5.35-6.51 years
Expected volatility		90.24%-104.99	%		91.14%-100.34	%
Expected dividends		0	%		0	%
Risk free interest rate		1.35%-3.15	%		1.81%-3.16	%

Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the years ended October 31, 2019 and 2018 was approximately $1.2 million and $3.7 million, respectively. Included in compensation expense for the year ended October 31, 2018 is approximately $77,000 recognized as a result of the modification of certain option agreements associated with two Board members that decided not to run for re-election in March 2018. For the modified options, the vesting was accelerated and the expiration dates were changed to the earlier of the original expiration date or March 21, 2023.

During the year ended October 31, 2019, 265,882 options were granted with a total grant date fair value of approximately $0.5 million. During the year ended October 31, 2018, 167,871 options were granted with a total grant date fair value of approximately $4.1 million.

As of October 31, 2019, there was approximately $1.3 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.65 years.

Employee Stock Purchase Plan

The Advaxis, Inc. 2018 Employee Stock Purchase Plan (ESPP) was approved by the Company’s shareholders on March 21, 2018. The 2018 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the 2018 ESPP beginning May 1, 2018. 1,000,000 shares of the Company’s Common stock are reserved for issuance under the 2018 ESPP.

During the year ended October 31, 2019, 7,435 shares were issued under the 2018 ESPP and the Company recorded an expense of approximately $2,000. During the year ended October 31, 2018, 2,611 shares were issued under the 2011 and 2018 ESPPs and the Company recorded an expense of approximately $7,000.

As of October 31, 2019, 990,665 shares of Company’s common stock remain available for issuance under the 2018 ESPP.

Collaboration and Licensing Agreements

12 Months Ended

Oct. 31, 2019

Business Combinations [Abstract]

Collaboration and Licensing Agreements

8. COLLABORATION AND LICENSING AGREEMENTS

OS Therapies LLC

On September 4, 2018, the Company granted a license to OS Therapies for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Pursuant to the agreement, the Company is to receive an upfront payment, reimbursement for product supply and other support, clinical, regulatory, and sales-based milestone payments, and royalties on future product sales.

Amgen

On August 1, 2016, the Company entered into a global agreement (the “Amgen Agreement”) with Amgen for the development and commercialization of the Company’s ADXS-NEO, a then- preclinical investigational immunotherapy, using the Company’s proprietary Listeria monocytogenes attenuated bacterial vector which activates a patient’s immune system to respond against unique mutations, or neoepitopes, contained in and identified from an individual patient’s tumor. Under the terms of the Amgen Agreement, Amgen received an exclusive worldwide license to develop and commercialize ADXS-NEO. Amgen made an upfront payment to Advaxis of $40 million and purchased directly from Advaxis 203,163 shares of the Company’s common stock, at approximately $123.00 per share (representing a purchase at market using a 20 day VWAP methodology) for a total of $25 million. Amgen assisted in funding the clinical development and commercialization of ADXS-NEO and Advaxis retained manufacturing responsibilities. Advaxis and Amgen collaborated through a joint steering committee for the development and commercialization of ADXS-NEO. Advaxis received reimbursements for research and development costs and Advaxis was eligible to receive future contingent payments based on development, regulatory and sales milestone payments of up to $475 million and high single digit to double digit royalty payments based on worldwide sales by Amgen.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Amgen, is a customer. The Company identified the following material promises under the arrangement: (1) licenses, (2) research and development activities, (3) clinical supplies, (4) regulatory responsibilities and (5) participation on a Joint Steering Committee (JSC). The Company determined that the licenses and research and development activities were not distinct from another, as the licenses had limited value without the performance of the research and development activities. Participation on the JSC to oversee the research and development activities was determined to be quantitatively and qualitatively immaterial and therefore was excluded from performance obligations. The clinical supply and regulatory responsibilities did not represent separate performance obligations based on their dependence on the research and development efforts. Based on this assessment, the Company identified one performance obligation at the outset of the Amgen Agreement, which consists of: (1) licenses, (2) research and development activities, (3) clinical supplies and (4) regulatory responsibilities.

Under the Amgen Agreement, in order to evaluate the appropriate transaction price, the Company determined that the upfront amount of $40 million constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which is allocated to the single performance obligation. The Company concluded that a time-based method was most appropriate to measuring progress toward completion given that the research and development services are satisfied reasonably evenly over the agreement and the Company has a stand-ready obligation to perform over such time. Accordingly, progress toward completion and related revenue recognition is measured using the input method of time elapsed relative to the estimated timeline for Advaxis to submit the Phase 2 package to Amgen, or perform the contractual research and development services, which was the predominant promise in the Company’s combined performance obligation to Amgen.

The reimbursement for the research and development costs was variable consideration that was included in the transaction price at the outset, subject to the constraint. The Company estimated the consideration from the reimbursement of the research and development costs using the most-likely amount. When the research and development costs are no longer constrained, they are added to the transaction price for the single, combined performance obligation and recognized over the same recognition period as the rest of the performance obligation’s allocated revenue. The potential milestone and sales-based royalty payments that the Company was eligible to receive were excluded from the transaction price, as all milestone and sales royalty amounts were fully constrained based on the probability of achievement. The Company reevaluated the transaction price at the end of each reporting period and as uncertain events were resolved or other changes in circumstances occurred, and, as necessary, adjusted its estimate of the transaction price.

On December 10, 2018, the Company received a written notice of termination from Amgen with respect to the Amgen Agreement. The termination became effective as of February 8, 2019, and the Company regained worldwide rights for the development and commercialization of its ADXS-NEO program. On October 24, 2019, Advaxis announced that it has enrolled its last patient in its ADXS-NEO program in monotherapy and will not enter Part B.

The remaining deferred revenue of approximately $18.2 million on December 10, 2018 related to the $40 million non-refundable, up-front payment received from Amgen was accounted for as of the modification date. As of that notification date, the Company adjusted revenue on a cumulative catch-up basis considering the revised measure of progress for the combined performance obligation based on the modified service period up to and through the contract termination date of February 8, 2019. The Company recognized cumulative catch-up revenue of approximately $15.6 million on December 10, 2018. The remaining $2.6 million was recognized over the subsequent 60 days until the performance obligation was satisfied on February 8, 2019.

During the years ended October 31, 2019 and 2018, the Company recognized revenue from the Amgen Agreement of approximately $20.6 million and $5.8 million, respectively. During the year ended October 31, 2018, Company recorded reductions in research and development expenses of approximately $5.8 million pertaining to the reimbursement of research and development costs. During the year ended October 31, 2019, the reimbursement of research and development costs of approximately $2.0 million was included in revenue.

Merck & Co., Inc.

On August 22, 2014, the Company entered into a Clinical Trial Collaboration and Supply Agreement (the “Merck Agreement”) with Merck, pursuant to which the parties collaborated on a Phase 1/2 dose-determination and safety trial. The Phase 1 portion of the trial evaluated the safety of our Lm -LLO based immunotherapy for prostate cancer, ADXS-PSA (the “Advaxis Compound”) as monotherapy and in combination with KEYTRUDA® (pembrolizumab), Merck’s humanized monoclonal antibody against PD-1, (the “Merck Compound”) and has determined a recommended Phase 2 combination dose. The Phase 2 portion evaluated the safety and efficacy of the Advaxis Compound in combination with the Merck Compound. Both phases of the trial were in patients with previously treated metastatic castration-resistant prostate cancer. The last patient was dosed in August 2019 and the Company is in the surveillance stage of the study. A joint development committee, comprised of equal representatives from both parties, is responsible for coordinating all regulatory and other activities under, and pursuant to, the Merck Agreement.

Each party is responsible for their own internal costs and expenses to support the trial, while the Company was responsible for all third party costs of conducting the trial. Merck was responsible for manufacturing and supplying the Merck Compound. The Company was responsible for manufacturing and supplying the Advaxis Compound. The Company is the sponsor of the trial and holds the IND related to the trial.

All data and results generated under the trial (“Collaboration Data”) will be jointly owned by the parties, except that ownership of data and information generated from sample analysis to be performed by each party on its respective compound will be owned by the party conducting such testing. All rights to all inventions and discoveries, which claim or cover the combined use of the Advaxis Compound and the Merck Compound shall belong jointly to the parties. Inventions and discoveries relating solely to the Advaxis Compound, or a live attenuated bacterial vaccine, shall be the exclusive property of Advaxis. Inventions and discoveries relating solely to the Merck Compound, or a PD-1 antagonist, shall be the exclusive property of Merck.

During the years ended October 31, 2019 and 2018, the Company incurred approximately $0.9 million and $2.4 million, respectively, in expenses pertaining to the Merck agreement, and such expenses were a component of research and development expenses in the statement of operations.

Elanco Animal Health (formerly Aratana Therapeutics)

On March 19, 2014, the Company and Aratana entered into a definitive Exclusive License Agreement (the “Aratana Agreement”). Pursuant to the Agreement, Advaxis granted Aratana an exclusive, worldwide, royalty-bearing, license, with the right to sublicense, certain Advaxis proprietary technology that enables Aratana to develop and commercialize animal health products that will be targeted for treatment of osteosarcoma and other cancer indications in animals. Under the terms of the Aratana Agreement, Aratana paid an upfront payment to the Company, of $1 million. As this license has stand-alone value to Aratana (who has the ability to sublicense) and was delivered to Aratana, upon execution of the Aratana Agreement, the Company recorded the $1 million payment as licensing revenue during the year ended October 31, 2014. Aratana will also pay the Company up to an additional $36.5 million based on the achievement of certain milestones with respect to the advancement of products pursuant to the terms of the Aratana Agreement. In addition, Aratana may pay the Company an additional $15 million in cumulative sales milestones pursuant to the terms of the Aratana Agreement.

During the year ended October 31, 2018, the USDA’s Center for Veterinary Biologics granted Aratana conditional approval for its canine osteosarcoma vaccine using Advaxis’ technology. During the years ended October 31, 2019 and 2018, Advaxis recognized royalty revenue totaling approximately $8,000 and $3,000, respectively, from Aratana’s sales of the canine osteosarcoma vaccine. On July 16, 2019, Aratana announced their shareholders approved a merger agreement with Elanco Animal Health (“Elanco”) whereby Elanco will be the majority shareholder in Aratana. All of the terms of the Aratana Agreement remain in effect.

Global BioPharma Inc.

On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (GBP), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC).

GBP is planning to conduct a randomized Phase 2, open-label, controlled trial in HPV-associated NSCLC in patients following first-line induction chemotherapy. GBP has obtained Taiwanese regulatory approval for this trial and plans to initiate this trial in late 2019 or early 2020. This trial will be fully funded exclusively by GBP and GBP will be responsible for all clinical development and commercialization costs in the GBP territory and GBP is committed to establishing manufacturing capabilities for its own. Under the terms of the agreement, the Company will exclusively license the rights of axalimogene filolisbac to GBP for the Asia, Africa, and former USSR territory, exclusive of India and certain other countries, for all HPV-associated indications. Advaxis will retain exclusive rights to axalimogene filolisbac for the rest of the world.

During each of the years ended October 31, 2019 and 2018, the Company recorded $0.25 million in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews. In addition, GBP paid $2.25 million to the contract research organization that manages the Company’s AIM2CERV clinical trial. On June 27, 2019, Advaxis announced that it is closing the AIM2CERV Phase 3 clinical trial with AXAL in high-risk locally advanced cervical cancer.

Commitments and Contingencies

12 Months Ended

Oct. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

Stendhal

On September 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013) relating to the Co-development and Commercialization Agreement with Especificos Stendhal SA de CV (the “Stendhal Agreement”). In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regarding its AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at the time and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking to recover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3 million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answered Stendhal’s Demand for Arbitration and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhal breached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and that Stendhal therefore owes the Company $3 million. Advaxis is also seeking fees associated with the arbitration and interest.

On April 2, 2019, the Arbitrator denied the Company’s early application for summary disposition of Stendhal’s claims. No reasoning was provided. From October 21-23, 2019, an evidentiary hearing for the arbitration was conducted, and on November 23, 2019, the arbitrator requested that the parties submit post-hearing briefs. The deadline for submission is January 15, 2020. Closing arguments may also get scheduled at a later date. At this time, the Company is unable to predict the likelihood of an unfavorable outcome.

Corporate Office & Manufacturing Facility Lease

The Company leases its corporate office and manufacturing facility under an operating lease expiring in November 2025.

Future minimum payments under the Company’s operating leases are as follows (in thousands):

Year ended October 31,

2020	$	1,233
2021		1,318
2022		1,369
2023		1,395
2024		1,419
Thereafter		1,564
Total	$	8,298

Rent expense for each of the years ended October 31, 2019 and 2018 was approximately $1.2 million.

Income Taxes

12 Months Ended

Oct. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

10. INCOME TAXES

The income tax provision (benefit) consists of the following (in thousands):

	October 31, 2019			October 31, 2018
Federal
Current	$	-		$	-
Deferred		32,673			22,325
State and Local
Current		-			-
Deferred		(1,634	)		(5,449	)
Change in valuation allowance		(31,039	)		(16,876	)
Income tax provision (benefit)	$	-		$	-

The Company has U.S. federal net operating loss carryovers (“NOLs”) of approximately $68.3 million and $265.8 million at October 31, 2019 and 2018 respectively, available to offset taxable income which expire beginning in 2023. If not used, these NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations. During the years ended October 31, 2019 and 2018, the Company performed a detailed analysis of any historical and/or current Section 382 ownership changes that may limit the utilization of the net operating loss carryovers. From the entire federal NOL of $278.1 million as of October 31, 2019, approximately $68.3 million is available for use based on Internal Revenue Code Section 382 analysis. The NOL and the deferred tax asset table below does not include approximately $209.8 million of NOL’s that may expire unused. The Company also has New Jersey State Net Operating Loss carryovers of approximately $116.6 million as of October 31, 2019 available to offset future taxable income through 2039.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon future generation for taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance.

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act made broad and significant changes to the U.S. tax code including, but not limited to, a change in the federal rate from 34% to 21%. As a result of the enactment of the legislation, the Company recorded a one-time reduction to its deferred tax assets of approximately $34.4 million, which was offset by a reduction in the valuation allowance.

When a U.S. federal tax rate change occurs during a fiscal year, taxpayers are required to compute a weighted daily average rate for the fiscal year of enactment. As a result of the Tax Act, Advaxis has calculated a blended U.S. federal statutory corporate income tax rate of approximately 23% for the year ended October 31, 2018 and applied this rate in computing the income tax provision for year ending October 31, 2018. The blended U.S. federal statutory corporate income tax rate of 23% is the weighted daily average rate between the pre-enactment U.S. federal statutory tax rate of 34% applicable to the Company’s 2018 fiscal year prior to the Effective Date and the post-enactment U.S. federal statutory tax rate of 21% applicable to the 2018 fiscal year thereafter. Advaxis expects the U.S. federal statutory rate to be 21% for fiscal years beginning after October 31, 2018.

The Company evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.

If applicable, interest costs related to the unrecognized tax benefits are required to be calculated and would be classified as other expense in the statement of operations. Penalties would be recognized as a component of general and administrative expenses in the statement of operations.

No interest or penalties on unpaid tax were recorded during the years ended October 31, 2019 and 2018, respectively. As of October 31, 2019 and 2018, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.

The Company files tax returns in the U.S. federal and state jurisdictions and is subject to examination by tax authorities beginning with the year ended October 31, 2016.

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following (in thousands):

	Years Ended
	October 31, 2019			October 31, 2018
Deferred Tax Assets
Net operating loss carryovers	$	22,627		$	65,002
Stock-based compensation		11,767			12,081
Research and development credits		10,234			6,843
Capitalized R&D costs		13,399			-
Deferred revenue		-			5,247
Other deferred tax assets		405			587
Total deferred tax assets	$	58,432		$	89,760
Valuation allowance		(56,822	)		(87,862	)
Deferred tax asset, net of valuation allowance	$	1,610		$	1,898

Deferred Tax Liabilities
Other deferred tax liabilities	$	(1,610	)	$	(1,898	)
Total deferred tax liabilities	$	(1,610	)	$	(1,898	)
Net deferred tax asset (liability)	$	-		$	-

The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Years Ended
	October 31, 2019			October 31, 2018
US Federal statutory rate		21.00	%		23.17	%
State income tax, net of federal benefit		9.84			8.19
Permanent differences		1.23			1.22
Research and development credits		17.30			(0.38	)
Change in valuation allowance		(47.02	)		25.37
Tax Cuts and Jobs Act		-			(53.93	)
Other		(2.34	)		(3.64	)
Income tax (provision) benefit		0.00	%		0.00	%

Sale of Net Operating Losses (NOLs)

The Company was eligible to receive cash from the sale of its Net Operating Losses under the State of New Jersey NOL Transfer Program. In January 2018, the Company received a net cash amount of approximately $4.5 million from the sale of its state NOLs and research and development tax credits for the year ended October 31, 2016. Following the receipt of the NOL and research and development tax credit for the year ending October 31, 2016, the Company reached the limit under the NJ NOL program.

Stockholders' Equity

12 Months Ended

Oct. 31, 2019

Equity [Abstract]

Stockholders' Equity

11. STOCKHOLDERS’ EQUITY

At-the-Market Transactions

During January 2018, the Company sold 58,776 shares of its common stock at-the-market transactions resulting in net proceeds of approximately $2.7 million.

Public Offerings

During February 2018, the Company closed on an underwritten public offering of 666,667 shares of the Company’s common stock in a public offering at $30.00 per share, for total gross proceeds of $20 million. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $18.4 million. The sale of the Offered Shares was registered pursuant to a Registration Statement (No. 333-216008) on Form S-3, as amended, which was filed by the Company with the Securities and Exchange Commission on March 17, 2017 and declared effective on March 20, 2017.

In September 2018, the Company closed on an underwritten public offering of 1,111,111 shares of its common stock and warrants to purchase up to 944,444 shares of common stock at a public offering price of $18.00, for gross proceeds of $20 million. Each share of common stock was sold together in a fixed combination with a warrant to purchase 0.85 shares of common stock. The warrants are exercisable immediately, expire six years from the date of issuance and have an exercise price of $22.50 per share, subject to anti-dilution adjustments (see Note 6). After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $18.2 million. The shares of common stock were sold pursuant to an effective shelf registration statement on Form S-3 (No. 333- 226988) filed with the Securities and Exchange Commission on August 23, 2018 and declared effective on August 30, 2018.

In April 2019, the Company issued 2,500,000 shares of the Company’s common stock in a public offering at $4.00 per share, less underwriting discounts and commissions. The net proceeds to the Company from the transaction was approximately $9 million.

In July 2019, the Company closed on an underwritten public offering of 10,650,000 shares of its common stock, pre-funded warrants to purchase 13,656,000 shares of common stock and warrants to purchase up to 17,142,000 shares of common stock for gross proceeds of $17.0 million. Each share of common stock was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock for $0.70, and each pre-funded warrant was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock for $0.699. The pre-funded warrants are exercisable immediately, do not expire and have an exercise price of $0.001 per share. The warrants are exercisable immediately, expire five years from the date of issuance, have an exercise price of $2.80 per share and are subject to anti-dilution and other adjustments for certain stock splits, stock dividends, or recapitalizations. The warrants also provide that if during the period of time between the date that is the earlier of (i) 30 days after issuance and (ii) if the common stock trades an aggregate of more than 35,000,000 shares after the pricing of the offering, and ending 15 months after issuance, the weighted-average price of common stock immediately prior to the exercise date is lower than the then-applicable exercise price per share, each Common Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $15.5 million.

Fair Value

12 Months Ended

Oct. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value

12. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2019 and October 31, 2018:

October 31, 2019	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	19	$	19

October 31, 2018	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $22.50 through September 2024		-		-	$	6,517	$	6,517

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities:

	Year Ended October 31,
	2019			2018
Beginning balance	$	6,517		$	-
Issuance of warrants		-			9,917
Shares issued in settlement of warrants		(3,856	)		-
Warrant exercises		(53	)		-
Change in fair value		(2,589	)		(3,400	)
Ending Balance	$	19		$	6,517

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Employee Benefit Plan

12 Months Ended

Oct. 31, 2019

Retirement Benefits [Abstract]

Employee Benefit Plan

13. EMPLOYEE BENEFIT PLAN

The Company sponsors a 401(k) Plan. Employees become eligible for participation upon the start of employment. Participants may elect to have a portion of their salary deferred and contributed to the 401(k) Plan up to the limit allowed under the Internal Revenue Code. The Company makes a matching contribution to the plan for each participant who has elected to make tax-deferred contributions for the plan year. The Company made matching contributions which amounted to approximately $0.2 million and $0.4 million for the years ended October 31, 2019 and 2018, respectively. These amounts were charged to the statement of operations. The employer contributions vest immediately.

Summary of Significant Accounting Policies and Basis of Presentation (Policies)

12 Months Ended

Oct. 31, 2019

Accounting Policies [Abstract]

Estimates

Estimates

Reclassification

Reclassification

Revenue Recognition

Revenue Recognition

Collaborative Arrangements

Collaborative Arrangements

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.

Concentration of Credit Risk

Concentration of Credit Risk

Restricted Cash and Letter of Credit

Restricted Cash and Letter of Credit

Deferred Expenses

Deferred Expenses

Deferred expenses consist of advanced payments made on research and development projects. Expense is recognized in the Statement of Operations as the research and development activity is performed.

Property and Equipment

Property and Equipment

When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

Intangible Assets

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Net Income (Loss) Per Share

Net Income (Loss) per Share

	As of October 31,
	2019		2018
Warrants		432,142		944,635
Stock options		560,490		330,071
Restricted stock units		14,706		32,614
Total		1,007,338		1,307,320

Research and Development Expenses

Research and Development Expenses

Stock Based Compensation

Stock Based Compensation

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Derivative Financial Instruments

Derivative Financial Instruments

Income Taxes

Income Taxes

Recent Accounting Standards

Recent Accounting Standards

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

	Impact of ASC 606 Adoption on Balance Sheet as of November 1, 2018
(in thousands)	As reported under ASC 606		Adjustments			Balances without adoption of ASC 606
Accounts receivable	$	1,664	$	1,664		$	-
Prepaid expenses and other current assets	$	1,611	$	(1,664	)	$	3,275

	Impact of ASC 606 Adoption on Balance Sheet as of October 31, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,433	$	-	$	1,433

	Impact of ASC 606 Adoption on Statement of Operations for the Year Ended October 31, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Revenue	$	20,884	$	1,960	$	18,924
Research and Development Expenses	$	30,320	$	1,960	$	28,360

	Impact of ASC 606 Adoption on Statement of Cash Flows for the Year Ended October 31, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,433		-		1,433

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Summary of Significant Accounting Policies and Basis of Presentation (Tables)

12 Months Ended

Oct. 31, 2019

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share

The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.

	As of October 31,
	2019		2018
Warrants		432,142		944,635
Stock options		560,490		330,071
Restricted stock units		14,706		32,614
Total		1,007,338		1,307,320

Schedule of Reclassifications to Balance Sheet and Income Statement

A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below (in thousands):

	Impact of ASC 606 Adoption on Balance Sheet as of November 1, 2018
(in thousands)	As reported under ASC 606		Adjustments			Balances without adoption of ASC 606
Accounts receivable	$	1,664	$	1,664		$	-
Prepaid expenses and other current assets	$	1,611	$	(1,664	)	$	3,275

	Impact of ASC 606 Adoption on Balance Sheet as of October 31, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,433	$	-	$	1,433

	Impact of ASC 606 Adoption on Statement of Operations for the Year Ended October 31, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Revenue	$	20,884	$	1,960	$	18,924
Research and Development Expenses	$	30,320	$	1,960	$	28,360

	Impact of ASC 606 Adoption on Statement of Cash Flows for the Year Ended October 31, 2019
(in thousands)	As reported under ASC 606		Adjustments		Balances without adoption of ASC 606
Accounts receivable	$	-	$	-	$	-
Prepaid expenses and other current assets	$	1,433		-		1,433

Property and Equipment (Tables)

12 Months Ended

Oct. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consists of the following (in thousands):

	October 31,
	2019			2018
Leasehold improvements	$	2,335		$	2,321
Laboratory equipment		3,405			5,510
Furniture and fixtures		744			746
Computer equipment		409			409
Construction in progress		83			17
Total property and equipment		6,976			9,003
Accumulated depreciation and amortization		(2,626	)		(2,319	)
Net property and equipment	$	4,350		$	6,684

Intangible Assets (Tables)

12 Months Ended

Oct. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

Intangible assets consist of the following (in thousands):

	October 31,
	2019			2018
Patents	$	5,833		$	5,970
License		777			777
Software		117			117
Total intangibles		6,727			6,864
Accumulated amortization		(2,152	)		(2,026	)
Net intangible assets	$	4,575		$	4,838

Schedule of Carrying Value of Intangible Assets

At October 31, 2019, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

2020	$	366
2021		346
2022		346
2023		346
2024		346
Thereafter		3,171
Total	$	4,575

Accrued Expenses (Tables)

12 Months Ended

Oct. 31, 2019

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

The following table represents the major components of accrued expenses (in thousands):

	October 31,
	2019		2018
Salaries and other compensation	$	158	$	2,035
Vendors		3,194		3,660
Professional fees		126		490
Total accrued expenses	$	3,478	$	6,185

Common Stock Purchase Warrants and Warrant Liability (Tables)

12 Months Ended

Oct. 31, 2019

Common Stock Purchase Warrants And Warrant Liability

Schedule of Outstanding Warrants

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	-		359,838	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		72,279	September 2024	September 2018 Public Offering
	Grand Total		432,142

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	281.25		25	N/A	Other Warrants
$	56.25		166	March 2019	March 2014 Public Offering- Placement Agent
$	22.50		944,444	September 2024	September 2018 Public Offering
	Grand Total		944,635

Schedule of Warrants Activity

A summary of warrant activity was as follows (In thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2017		206,160		$	75.00		.92	$	-
Issued		944,444			22.50
Expired		(205,969	)		75.00
Outstanding and exercisable warrants at October 31, 2018		944,635		$	22.50		5.87	$	-
Issued		31,885,500
Exercised *		(31,540,962	)
Exchanged		(856,865	)
Expired		(166	)
Outstanding and exercisable warrants at October 31, 2019		432,142		$	0.08		4.76	$	114,069

* Includes the cashless exercise of 17,869,662 warrants that resulted in the issuance of 17,869,662 shares of common stock.

Schedule of Assumptions Used in Warrant Liability

In measuring the warrant liability, the Company used the following inputs in its Monte Carlo simulation model:

	October 31, 2019			October 31, 2018
Exercise Price	$	0.37		$	22.50
Stock Price	$	0.32		$	8.40
Expected Term		4.87 years			5.87 years
Volatility %		100.99	%		97.47	%
Risk Free Rate		1.51	%		3.03	%

Share Based Compensation (Tables)

12 Months Ended

Oct. 31, 2019

Share-based Payment Arrangement [Abstract]

Summary of Share Based Compensation Expense

The following table summarizes share-based compensation expense included in the statement of operations by expense category for the years ended October 31, 2019 and 2018 (in thousands):

	Year Ended October 31,
	2019		2018
Research and development	$	1,036	$	2,836
General and administrative		966		4,147
Total	$	2,002	$	6,983

Summary of RSU Activity and Related Information

A summary of the Company’s RSU activity and related information for the year ended October 31, 2019 and 2018 is as follows:

	Number of RSU’s			Weighted-Average Grant Date Fair Value
Unvested as of October 31, 2017		90,870		$	128.10
Granted		27,330			29.55
Vested		(53,873	)		115.65
Cancelled		(31,713	)		123.45
Unvested as of October 31, 2018		32,614		$	70.41
Vested		(12,257	)		78.41
Cancelled		(5,651	)		112.39
Unvested as of October 31, 2019		14,706		$	47.62

Summary of Changes in Stock Option Plan

A summary of changes in the stock option plan for the years ended October 31, 2019 and 2018 is as follows (in thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding as of October 31, 2017		259,571		$	187.65		5.72	$	-
Granted		167,871			30.90
Cancelled or expired		(97,371	)		137.10
Outstanding as of October 31, 2018		330,071		$	122.79		6.56	$	-
Granted		265,882			2.36
Cancelled or expired		(35,463	)		29.52
Outstanding as of October 31, 2019		560,490		$	71.56		7.34	$	1
Vested and exercisable at October 31, 2019		240,015		$	155.25		4.50	$	-

Summary of Outstanding and Exercisable Options

The following table summarizes information about the outstanding and exercisable options at October 31, 2019:

Options Outstanding										Options Exercisable
				Weighted		Weighted						Weighted		Weighted
				Average		Average						Average		Average
Exercise		Number		Remaining		Exercise		Intrinsic		Number		Remaining		Exercise		Intrinsic
Price Range		Outstanding		Contractual		Price		Value		Exercisable		Contractual		Price		Value
$	.30-$10.00		249,329		9.69	$	2.35	$	1		178		8.98	$	9.00	$	-
$	10.01-$100.00		119,753		8.53	$	29.70	$	-		52,846		8.17	$	34.15	$	-
$	100.01-$200.00		101,490		3.97	$	167.11	$	-		97,073		3.85	$	169.45	$	-
$	200.01-$318.75		89,918		3.04	$	211.39	$	-		89,918		3.04	$	211.39	$	-

Summary of Fair Value of Stock Options Granted of BSM

The following table provides the weighted average fair value of options granted to directors and employees and the related assumptions used in the Black-Scholes model:

	Year Ended
	October 31, 2019			October 31, 2018
Weighted average fair value of options granted	$	1.84		$	1.61
Expected term		5.50-6.51 years			5.35-6.51 years
Expected volatility		90.24%-104.99	%		91.14%-100.34	%
Expected dividends		0	%		0	%
Risk free interest rate		1.35%-3.15	%		1.81%-3.16	%

Commitments and Contingencies (Tables)

12 Months Ended

Oct. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Summary of Future Minimum Payments of Operating Leases

Future minimum payments under the Company’s operating leases are as follows (in thousands):

Year ended October 31,

2020	$	1,233
2021		1,318
2022		1,369
2023		1,395
2024		1,419
Thereafter		1,564
Total	$	8,298

Income Taxes (Tables)

12 Months Ended

Oct. 31, 2019

Income Tax Disclosure [Abstract]

Schedule of Income Tax Provision (Benefit)

The income tax provision (benefit) consists of the following (in thousands):

	October 31, 2019			October 31, 2018
Federal
Current	$	-		$	-
Deferred		32,673			22,325
State and Local
Current		-			-
Deferred		(1,634	)		(5,449	)
Change in valuation allowance		(31,039	)		(16,876	)
Income tax provision (benefit)	$	-		$	-

Schedule of Deferred Tax Assets (Liabilities)

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following (in thousands):

	Years Ended
	October 31, 2019			October 31, 2018
Deferred Tax Assets
Net operating loss carryovers	$	22,627		$	65,002
Stock-based compensation		11,767			12,081
Research and development credits		10,234			6,843
Capitalized R&D costs		13,399			-
Deferred revenue		-			5,247
Other deferred tax assets		405			587
Total deferred tax assets	$	58,432		$	89,760
Valuation allowance		(56,822	)		(87,862	)
Deferred tax asset, net of valuation allowance	$	1,610		$	1,898

Deferred Tax Liabilities
Other deferred tax liabilities	$	(1,610	)	$	(1,898	)
Total deferred tax liabilities	$	(1,610	)	$	(1,898	)
Net deferred tax asset (liability)	$	-		$	-

Schedule of Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit

The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Years Ended
	October 31, 2019			October 31, 2018
US Federal statutory rate		21.00	%		23.17	%
State income tax, net of federal benefit		9.84			8.19
Permanent differences		1.23			1.22
Research and development credits		17.30			(0.38	)
Change in valuation allowance		(47.02	)		25.37
Tax Cuts and Jobs Act		-			(53.93	)
Other		(2.34	)		(3.64	)
Income tax (provision) benefit		0.00	%		0.00	%

Fair Value (Tables)

12 Months Ended

Oct. 31, 2019

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2019 and October 31, 2018:

October 31, 2019	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	19	$	19

October 31, 2018		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $22.50 through September 2024			-				-			$	6,517			$	6,517

Schedule of Changes in Fair Value of Warrant Liabilities

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities:

	Year Ended October 31,
	2019			2018
Beginning balance	$	6,517		$	-
Issuance of warrants		-			9,917
Shares issued in settlement of warrants		(3,856	)		-
Warrant exercises		(53	)		-
Change in fair value		(2,589	)		(3,400	)
Ending Balance	$	19		$	6,517

Nature of Operations and Basis of Presentation (Details Narrative) - USD ($) $ in Thousands	12 Months Ended		72 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019
Proceeds from public offering	$ 27,000		$ 292,200
Cash and cash equivalents	32,363	$ 44,141	$ 32,363
Operating expenses	38,856	$ 76,442
Fiscal Year 2020 [Member]
Operating expenses	29,000
Non-recurring costs	$ 6,000

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Concentration at credir risk	$ 30,900
Restricted cash balance		$ 977
Right to use asset	5,300
Lease liability	$ 6,600
Minimum [Member]
Estimated useful lives of property and equipment	3 years
Estimated useful life of intangible assets	3 years
Maximum [Member]
Estimated useful lives of property and equipment	10 years
Estimated useful life of intangible assets	20 years

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities, share	1,007,338	1,307,320
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities, share	432,142	944,635
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities, share	560,490	330,071
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities, share	14,706	32,614

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Reclassifications to Balance Sheet and Income Statement (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Nov. 02, 2018
Accounts receivable		$ 1,664	$ 1,664
Prepaid expenses and other current assets	1,433	1,611	1,611
Revenue	20,884	6,063
Research and Development Expenses	26,677	56,970
Accounts receivable	1,664	(153)
Prepaid expenses and other current assets	(103)	$ 836
Adjustments [Member]
Accounts receivable			1,664
Prepaid expenses and other current assets			(1,664)
Revenue	1,960
Research and Development Expenses	1,960
Accounts receivable
Prepaid expenses and other current assets
Balances Without Adoption of ASC 606 [Member]
Accounts receivable
Prepaid expenses and other current assets	1,433		$ 3,275
Revenue	18,924
Research and Development Expenses	28,360
Accounts receivable
Prepaid expenses and other current assets	$ 1,433

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,097	$ 1,113
Laboratory equipment, disposed	300	600
Impairment loss on idle laboratory equipment	$ 900	$ 0

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Oct. 31, 2018
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,335	$ 2,321
Laboratory equipment	3,405	5,510
Furniture and fixtures	744	746
Computer equipment	409	409
Construction in progress	83	17
Total property and equipment	6,976	9,003
Accumulated depreciation and amortization	(2,626)	(2,319)
Net property and equipment	$ 4,350	$ 6,684

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived patents expirations year	The expirations of the existing patents range from 2019 to 2039
Book value patent applications, net	$ 1,104	$ 1,047
Intangible asset amortization expense	$ 386	$ 388

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Oct. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 5,833	$ 5,970
License	777	777
Software	117	117
Total intangibles	6,727	6,864
Accumulated amortization	(2,152)	(2,026)
Net Intangible assets	$ 4,575	$ 4,838

Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) $ in Thousands	Oct. 31, 2019 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 366
2021	346
2022	346
2023	346
2024	346
Thereafter	3,171
Total	$ 4,575

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Oct. 31, 2018
Payables and Accruals [Abstract]
Salaries and other compensation	$ 158	$ 2,035
Vendors	3,194	3,660
Professional fees	126	490
Total accrued expenses	$ 3,478	$ 6,185

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) $ in Thousands		1 Months Ended			12 Months Ended
	Mar. 14, 2019 USD ($) $ / shares shares	Jul. 31, 2019 $ / shares shares	Apr. 30, 2019 $ / shares shares	Jan. 31, 2018 shares	Oct. 31, 2019 USD ($) $ / shares shares	Oct. 31, 2018 USD ($) $ / shares shares	Sep. 11, 2018 USD ($) $ / shares	Oct. 31, 2017 USD ($)
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock \| shares					432,142	944,635
Exercise price					$ 0.372	$ 22.50
Warrants outstanding \| shares					432,142	944,635
Number of common stock shares issued \| shares					17,869,662
Loss on shares issued in settlement of warrants \| $					$ (1,607)
Number of common stock shares sold \| shares				58,776
Fair value of the warrant liability \| $					19	6,517
Income on fair value of warrants \| $					$ 2,600	$ 3,400
Exercise Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	22.50						12.75
Stock Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	6.45						22.50
Expected Term [Member]
Class of Warrant or Right [Line Items]
Warrants, term	5 years 6 months						6 years
Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input fair value, percentage	96.37%						99.21%
Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input fair value, percentage	2.44%						2.91%
Private Exchange Agreement [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock \| shares	856,865
Exercise price	$ 22.50
Warrant expiration	Sep. 11, 2024
Private Exchange Agreement [Member] \| Investor [Member]
Class of Warrant or Right [Line Items]
Number of common stock shares issued \| shares	856,865
Fair value of warrant \| $	$ 3,900
Equity Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding \| shares					359,863	191
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding \| shares					72,279	944,444
Warrants, term						6 years
Number of common stock shares sold \| shares		10,650,000	2,500,000
Fair value of the warrant liability \| $					$ 19	$ 6,517
Income on fair value of warrants \| $					$ (2,589)	$ (3,400)
Warrant Liability [Member] \| Pre-funded Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock \| shares		13,656,000
Warrant Liability [Member] \| Exercise Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input					0.37	22.50
Warrant Liability [Member] \| Stock Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input					0.32	8.40
Warrant Liability [Member] \| Expected Term [Member]
Class of Warrant or Right [Line Items]
Warrants, term					4 years 10 months 14 days	5 years 10 months 14 days
Warrant Liability [Member] \| Investor [Member]
Class of Warrant or Right [Line Items]
Fair value of warrant \| $							$ 9,900
Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price						$ 22.50
Warrants outstanding \| shares						944,444
Warrants, term						6 years
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price					$ 0	$ 22.50
Minimum [Member] \| Private Exchange Agreement [Member]
Class of Warrant or Right [Line Items]
Exercise price	$ 4.50
Minimum [Member] \| Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Exercise price		$ 0.372	$ 3.72
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price					$ 281.25	$ 281.25
Maximum [Member] \| Private Exchange Agreement [Member]
Class of Warrant or Right [Line Items]
Exercise price	$ 22.50
Maximum [Member] \| Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Exercise price		$ 3.72	$ 4.50

Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 22.50
Number of Shares Underlying Warrants	432,142	944,635
Exercise Price Range One [Member]
Class of Warrant or Right [Line Items]
Exercise Price		$ 281.25
Number of Shares Underlying Warrants	359,838	25
Expiration Date	Jul. 31, 2024
Summary of Warrants	July 2019 Public Offering	Other Warrants
Exercise Price Range Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 281.25	$ 56.25
Number of Shares Underlying Warrants	25	166
Expiration Date		Mar. 31, 2019
Summary of Warrants	Other Warrants	March 2014 Public Offering- Placement Agent
Exercise Price Range Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 22.50
Number of Shares Underlying Warrants	72,279	944,444
Expiration Date	Sep. 30, 2024	Sep. 30, 2024
Summary of Warrants	September 2018 Public Offering	September 2018 Public Offering

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands

12 Months Ended

Oct. 31, 2019

Oct. 31, 2018

Common Stock Purchase Warrants And Warrant Liability

Number of Warrants, Outstanding and exercisable warrants, Beginning balance

944,635

206,160

Number of Warrants, Issued

31,885,500

944,444

Number of Warrants, Exercised

^[1]

(31,540,962)

Number of Warrants, Exchanged

(856,865)

Number of Warrants, Expired

(166)

(205,969)

Number of Warrants, Outstanding and exercisable warrants, Ending balance

432,142

944,635

Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning

$ 22.50

$ 75.00

Weighted Average Exercise Price, Issued

22.50

Weighted Average Exercise Price, Expired

75.00

Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending

$ 0.08

$ 22.50

Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning

5 years 10 months 14 days

11 months 1 day

Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance

4 years 9 months 3 days

5 years 10 months 14 days

Aggregate Intrinsic Value, Beginning

Aggregate Intrinsic Value, Ending

$ 114,069

[1]	Includes the cashless exercise of 17,869,662 warrants that resulted in the issuance of 17,869,662 shares of common stock.

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) (Parenthetical)	12 Months Ended
	Oct. 31, 2019 shares
Common Stock Purchase Warrants And Warrant Liability
Cashless warrant exercise	17,869,662
Number of common stock shares issued	17,869,662

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) - $ / shares	Oct. 31, 2019	Mar. 14, 2019	Oct. 31, 2018	Sep. 11, 2018
Exercise Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input		22.50		12.75
Stock Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input		6.45		22.50
Expected Term [Member]
Class of Warrant or Right [Line Items]
Warrants, term		5 years 6 months		6 years
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrants, term			6 years
Warrant Liability [Member] \| Exercise Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.37		22.50
Warrant Liability [Member] \| Stock Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.32		8.40
Warrant Liability [Member] \| Expected Term [Member]
Class of Warrant or Right [Line Items]
Warrants, term	4 years 10 months 14 days		5 years 10 months 14 days
Warrant Liability [Member] \| Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input percentage	100.99%		97.47%
Warrant Liability [Member] \| Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input percentage	1.51%		3.03%

Share Based Compensation (Details Narrative) - USD ($) $ in Thousands					1 Months Ended	12 Months Ended
	Mar. 29, 2019	Mar. 21, 2018	Jan. 02, 2018	Apr. 05, 2017	Jan. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Feb. 21, 2019	Jan. 02, 2019	Mar. 10, 2016
Issuance of common stock					58,776
Common stock authorized for issuance						170,000,000	170,000,000
Common stock, shares outstanding						50,201,671	4,634,189
Reverse stock split, description	1 for 15 reverse stock split
Unrecognized compensation cost related to non-vested stock option awards						$ 1,300
Unrecognized compensation cost related to non-vested remaining weighted average vesting period						1 year 7 months 24 days
Stock compensation expense						$ 2,002	$ 6,983
Compensation cost related to outstanding stock options						$ 1,200	$ 3,700
Number of options, granted						265,882	167,871
Fair value of option granted						$ 500	$ 4,100
Share-based compensation options expiration date						Mar. 21, 2023
Expenses recorded under employee stock purchase plan						$ 20	43
Two Board Members [Member]
Stock compensation expense						77
Restricted Stock Units (RSUs) [Member]
Fair value of equity purchases value						51	1,600
Unrecognized compensation cost related to non-vested stock option awards						$ 300
Unrecognized compensation cost related to non-vested remaining weighted average vesting period						1 year 2 months 12 days
Aggregate intrinsic value of non-vested RSU						$ 5
Restricted Stock Units (RSUs) [Member] \| Chief Financial Officer [Member]
Stock compensation expense							100
Restricted Stock Units (RSUs) [Member] \| Chief Operating Officer [Member]
Stock compensation expense							$ 300
Employee Stock Awards [Member]
Share-based compensation, common stock, shares						12,245	48,874
Share-based compensation, shares on net basis after employee payroll taxes						45,830	45,830
Stock compensation expense						$ 800	$ 3,100
Director Stock Awards [Member]
Stock compensation expense						$ 0	$ 200
Issuance of common stock issued for share based compensation						0	5,000
Maximum [Member]
Common stock authorized for issuance								170,000,000
Minimum [Member]
Common stock authorized for issuance								95,000,000
2015 Plan [Member]
Shares of common stock outstanding, percentage			5.00%	5.00%
Common stock, shares outstanding			137,743	166,667					166,667
Common stock reserved for issuance under plan						26,161
2015 Plan [Member] \| Maximum [Member]
Common stock authorized for issuance		95,000,000		406,667		65,000,000				306,667
2015 Plan [Member] \| Minimum [Member]
Common stock authorized for issuance		65,000,000		306,667		45,000,000				240,000
2015 Plan [Member] \| Additional Shares [Member] \| Maximum [Member]
Issuance of common stock						43,333
2018 Employee Stock Purchase Plan [Member]
Common stock reserved for issuance under plan		1,000,000
Discount price percentage		15.00%
Employee stock purchase plan description		The Company's shareholders on March 21, 2018. The 2018 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the 2018 ESPP beginning May 1, 2018. 1,000,000 shares of the Company's Common stock are reserved for issuance under the 2018 ESPP.
2018 Employee Stock Purchase Plan [Member]
Common stock reserved for issuance under plan						990,665
Number of shares issued under employee stock purchase plan						7,435
Expenses recorded under employee stock purchase plan						$ 2
2011 & 2018 Employee Stock Purchase Plans [Member]
Number of shares issued under employee stock purchase plan							2,611
Expenses recorded under employee stock purchase plan							$ 7
Stock Split [Member] \| 2015 Plan [Member]
Issuance of common stock						240,000

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Share-based compensation expense	$ 2,002	$ 6,983
Research and Development [Member]
Share-based compensation expense	1,036	2,836
General and Administrative [Member]
Share-based compensation expense	$ 966	$ 4,147

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Number of RSUs, Unvested Beginning Balance	32,614	90,870
Number of RSUs, Granted		27,330
Number of RSUs, Vested	(12,257)	(53,873)
Number of RSUs, Cancelled	(5,651)	(31,713)
Number of RSUs, Unvested Ending Balance	14,706	32,614
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance	$ 70.41	$ 128.10
Weighted-Average Grant Date Fair Value, Granted		29.55
Weighted-Average Grant Date Fair Value, Vested	78.41	115.65
Weighted-Average Grant Date Fair Value, Cancelled	112.39	123.45
Weighted-Average Grant Date Fair Value, Unvested Ending Balance	$ 47.62	$ 70.41

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Share-based Payment Arrangement [Abstract]
Number of Options, Beginning Balance	330,071	259,571
Number of Options, Granted	265,882	167,871
Number of Options, Cancelled or Expired	(35,463)	(97,371)
Number of Options, Ending Balance	560,490	330,071
Number of Options, Vested and Exercisable	240,015
Weighted-Average Exercise Price, Outstanding, Beginning	$ 122.79	$ 187.65
Weighted-Average Exercise Price, Granted	2.36	30.90
Weighted-Average Exercise Price, Cancelled or Expired	29.52	137.10
Weighted-Average Exercise Price, Outstanding, Ending	71.56	$ 122.79
Weighted-Average Exercise Price, Vested and Exercisable	$ 155.25
Weighted Average Remaining Contractual Life In Years, Outstanding, Beginning	6 years 6 months 21 days	5 years 8 months 19 days
Weighted Average Remaining Contractual Life In Years, Outstanding, Ending balance	7 years 4 months 2 days	6 years 6 months 21 days
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable	4 years 6 months
Aggregate Intrinsic Value, Beginning
Aggregate Intrinsic Value, Ending	1
Aggregate Intrinsic Value, Vested and Exercisable

Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Options Outstanding, Number Outstanding	560,490	330,071	259,571
Options Weighted Average Remaining Contractual Term	6 years 6 months 21 days	5 years 8 months 19 days
Options Outstanding, Weighted Average Exercise Price	$ 71.56	$ 122.79	$ 187.65
Options Outstanding, Intrinsic Value	$ 1
Options Exercisable, Number Outstanding	240,015
Options Exercisable, Weighted Average Exercise Price	$ 155.25
Options Exercisable, Intrinsic Value
Exercise Price Range One [Member]
Range, lower limit	$ 0.30
Range, upper limit	$ 10.00
Options Outstanding, Number Outstanding	249,329
Options Weighted Average Remaining Contractual Term	9 years 8 months 9 days
Options Outstanding, Weighted Average Exercise Price	$ 2.35
Options Outstanding, Intrinsic Value	$ 1
Options Exercisable, Number Outstanding	178
Options Weighted Average Remaining Contractual Term Exercisable	8 years 11 months 23 days
Options Exercisable, Weighted Average Exercise Price	$ 9.00
Options Exercisable, Intrinsic Value
Exercise Price Range Two [Member]
Range, lower limit	$ 10.01
Range, upper limit	$ 100.00
Options Outstanding, Number Outstanding	119,753
Options Weighted Average Remaining Contractual Term	8 years 6 months 10 days
Options Outstanding, Weighted Average Exercise Price	$ 29.70
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	52,846
Options Weighted Average Remaining Contractual Term Exercisable	8 years 2 months 1 day
Options Exercisable, Weighted Average Exercise Price	$ 34.15
Options Exercisable, Intrinsic Value
Exercise Price Range Three [Member]
Range, lower limit	$ 100.01
Range, upper limit	$ 200.00
Options Outstanding, Number Outstanding	101,490
Options Weighted Average Remaining Contractual Term	3 years 11 months 19 days
Options Outstanding, Weighted Average Exercise Price	$ 167.11
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	97,073
Options Weighted Average Remaining Contractual Term Exercisable	3 years 10 months 6 days
Options Exercisable, Weighted Average Exercise Price	$ 169.45
Options Exercisable, Intrinsic Value
Exercise Price Range Four [Member]
Range, lower limit	$ 200.01
Range, upper limit	$ 318.75
Options Outstanding, Number Outstanding	89,918
Options Weighted Average Remaining Contractual Term	3 years 15 days
Options Outstanding, Weighted Average Exercise Price	$ 211.39
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	89,918
Options Weighted Average Remaining Contractual Term Exercisable	3 years 15 days
Options Exercisable, Weighted Average Exercise Price	$ 211.39
Options Exercisable, Intrinsic Value

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details) - $ / shares	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Weighted average fair value of options granted	$ 1.84	$ 1.61
Expected Dividends	0.00%	0.00%
Minimum [Member]
Expected Term	5 years 6 months	5 years 4 months 6 days
Expected Volatility	90.24%	91.14%
Risk Free Interest Rate	1.35%	1.81%
Maximum [Member]
Expected Term	6 years 6 months 3 days	6 years 6 months 3 days
Expected Volatility	104.99%	100.34%
Risk Free Interest Rate	3.15%	3.16%

Collaboration and Licensing Agreements (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					12 Months Ended
	Feb. 08, 2019	Dec. 10, 2018	Aug. 02, 2016	Mar. 19, 2014	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2014
Number of common stock shares issued					17,869,662
Value of stock purchased					$ 24,471	$ 26,670
Revenue					20,884	6,063
Global BioPharma, Inc [Member]
Payment to contract research organization					2,250
License and Service [Member] \| Global BioPharma, Inc [Member]
Revenue					250	250
Merck Agreement [Member]
Agreement expenses					900	2,400
Amgen Agreement [Member]
Upfront payment			$ 40,000
Number of common stock shares issued			203,163
Share issued price per share			$ 123.00
Value of stock purchased			$ 25,000
Development, regulatory and sales milestone payments			475,000
Upfront payment recorded as deferred revenue		$ 40,000	$ 40,000
Deferred revenue		18,200
Cumulative catch-up revenue	$ 2,600	$ 15,600
Revenue					20,600	5,800
Reduction in research and development expenses					2,000	5,800
Aratana Agreement [Member]
Upfront payment				$ 1,000
Development, regulatory and sales milestone payments				36,500
Licensing revenue							$ 1,000
Additional, cumulative sales milestone payments				$ 15,000
Aratana Agreement [Member] \| Royalty [Member]
Revenue					$ 8	$ 3

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands		12 Months Ended
	Sep. 19, 2018	Oct. 31, 2019	Oct. 31, 2018
Rent expense		$ 1,200	$ 1,200
Corporate Office and Manufacturing Facility Lease [Member]
Operating lease expiring date		Nov. 30, 2025
Especificos Stendhal SA de CV [Member]
Damages sought value by plaintiff	$ 3,000
Litigation expense	300
Due from related party	$ 3,000

Commitments and Contingencies - Summary of Future Minimum Payments of Operating Leases (Details) $ in Thousands	Oct. 31, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 1,233
2021	1,318
2022	1,369
2023	1,395
2024	1,419
Thereafter	1,564
Total	$ 8,298

Income Taxes (Details Narrative) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
Income Taxes (Details Narrative) - USD ($) $ in Thousands	Dec. 22, 2017	Jan. 31, 2018	Oct. 31, 2019	Oct. 31, 2018
Net operating loss carry-forward			$ 68,300	$ 265,800
Operating loss expiration year			2023
Income tax reconciliation description	The U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the 'Tax Act"). The Tax Act made broad and significant changes to the U.S. tax code including, but not limited to, a change in the federal rate from 34% to 21%. As a result of the enactment of the legislation, the Company recorded a one-time reduction to its deferred tax assets of approximately $34.4 million, which was offset by a reduction in the valuation allowance. When a U.S. federal tax rate change occurs during a fiscal year, taxpayers are required to compute a weighted daily average rate for the fiscal year of enactment. As a result of the Tax Act, Advaxis has calculated a blended U.S. federal statutory corporate income tax rate of approximately 23% for the year ended October 31, 2018 and applied this rate in computing the income tax provision for year ending October 31, 2018. The blended U.S. federal statutory corporate income tax rate of 23% is the weighted daily average rate between the pre-enactment U.S. federal statutory tax rate of 34% applicable to the Company's 2018 fiscal year prior to the Effective Date and the post-enactment U.S. federal statutory tax rate of 21% applicable to the 2018 fiscal year thereafter. Advaxis expects the U.S. federal statutory rate to be 21% for fiscal years beginning after October 31, 2018.		NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations.
Total net operating loss carry-forward			$ 278,100
Net operating loss and deferred tax asset does not include nol's			209,800
New jersey state net operating loss carryovers			$ 116,600
Income tax effective tax rate	21.00%		0.00%	0.00%
Deferred tax assets	$ 34,400		$ 58,432	$ 89,760
Amount received from sale of net operating losses		$ 4,500
Internal Revenue Code [Member]
Net operating loss carry-forward			$ 68,300

Income Taxes - Schedule of Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Income Tax Disclosure [Abstract]
Federal Current
Federal Deferred	32,673	22,325
State and Local Current
State and Local Deferred	(1,634)	(5,449)
Change in valuation allowance	(31,039)	(16,876)
Income tax provision (benefit)	$ 50	$ 50

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Oct. 31, 2018	Dec. 22, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryovers	$ 22,627	$ 65,002
Stock-based compensation	11,767	12,081
Research and development credits	10,234	6,843
Capitalized R&D costs	13,399
Deferred revenue		5,247
Other deferred tax assets	405	587
Total deferred tax assets	58,432	89,760	$ 34,400
Valuation allowance	(56,822)	(87,862)
Deferred tax asset, net of valuation allowance	1,610	1,898
Other deferred tax liabilities	(1,610)	(1,898)
Total deferred tax liabilities	(1,610)	(1,898)
Net deferred tax asset (liability)

Income Taxes - Schedule of Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit (Details)		12 Months Ended
	Dec. 22, 2017	Oct. 31, 2019	Oct. 31, 2018
Income Tax Disclosure [Abstract]
US Federal statutory rate		21.00%	23.17%
State income tax, net of federal benefit		9.84%	8.19%
Permanent differences		1.23%	1.22%
Research and development credits		17.30%	(0.38%)
Change in valuation allowance		(47.02%)	25.37%
Tax Cuts and Jobs Act		0.00%	(53.93%)
Other		(2.34%)	(3.64%)
Income tax (provision) benefit	21.00%	0.00%	0.00%

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					12 Months Ended		72 Months Ended
	Jul. 31, 2019	Apr. 30, 2019	Sep. 30, 2018	Feb. 28, 2018	Jan. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019
Number of common stock shares sold					58,776
Proceeds from sale of common shares					$ 2,700
Number of shares issued, shares						17,869,662
Number of shares issued, value						$ 24,471	$ 26,670
Net proceeds from offering						$ 27,000		$ 292,200
Number of warrants to purchase common stock						432,142	944,635	432,142
Common Stock [Member]
Number of shares issued, shares						13,150,000	1,777,778
Number of shares issued, value						$ 13	$ 2
Public Offering [Member]
Number of shares issued, shares		2,500,000		666,667
Share price per share		$ 4.00	$ 18.00	$ 30.00
Number of shares issued, value		$ 9,000		$ 20,000
Net proceeds from offering				$ 18,400
Underwritten Public Offering [Member]
Number of shares issued, shares	10,650,000		1,111,111
Number of shares issued, value	$ 17,000		$ 20,000
Net proceeds from offering	$ 15,500		$ 18,200
Number of warrants to purchase common stock			944,444
Sale of stock price per share			$ 0.85
Warrants, term	5 years		6 years
Sold price per share transaction	Each share of common stock was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock for $0.70, and each pre-funded warrant was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock for $0.699. The pre-funded warrants are exercisable immediately, do not expire and have an exercise price of $0.001 per share. The warrants are exercisable immediately, expire five years from the date of issuance, have an exercise price of $2.80 per share and are subject to anti-dilution and other adjustments for certain stock splits, stock dividends, or recapitalizations. The warrants also provide that if during the period of time between the date that is the earlier of (i) 30 days after issuance and (ii) if the common stock trades an aggregate of more than 35,000,000 shares after the pricing of the offering, and ending 15 months after issuance, the weighted-average price of common stock immediately prior to the exercise date is lower than the then-applicable exercise price per share, each Common Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock.
Underwritten Public Offering [Member] \| Maximum [Member]
Number of warrants to purchase common stock	17,142,000
Underwritten Public Offering [Member] \| Common Stock [Member]
Sale of stock price per share	$ 0.70
Underwritten Public Offering [Member] \| Pre-funded Warrants [Member]
Number of warrants to purchase common stock	13,656,000
Sale of stock price per share	$ 0.75

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Oct. 31, 2019	Oct. 31, 2018
Common stock warrant liability, warrants exercisable	$ 19	$ 6,517
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 19	$ 6,517

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	Oct. 31, 2019	Oct. 31, 2018
Fair Value Disclosures [Abstract]
Warrant exercise price per share	$ 0.372	$ 22.50

Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Beginning balance	$ 6,517
Warrant exercises	122
Change in fair value	2,600	$ 3,400
Ending Balance	19	6,517
Warrant Liability [Member]
Beginning balance	6,517
Issuance of warrants		9,917
Shares issued in settlement of warrants	(3,856)
Warrant exercises	(53)
Change in fair value	(2,589)	(3,400)
Ending Balance	$ 19	$ 6,517

Employee Benefit Plan (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
401(k) Plan [Member]
Employee contributions, amount	$ 200	$ 400